AGENDIA NV

Their core work

Agendia is an Amsterdam-based molecular diagnostics company specializing in genomic tests for cancer. Their flagship product, MammaPrint, is a multi-gene expression assay that helps clinicians decide whether early-stage breast cancer patients actually need chemotherapy — potentially sparing women from unnecessary treatment. They commercialize clinical diagnostics built on gene-expression profiling and run the laboratory infrastructure to deliver these tests to hospitals across Europe and the US.

What they specialise in

How they've shifted over time

With only two projects, both launched in 2015, there is no meaningful temporal shift to analyze. Both engagements reinforce a single specialization in gene-expression-based cancer diagnostics — one in breast cancer (their core product) and one extending the approach into colorectal cancer via a partner-led trial.

Their H2020 footprint is small but commercially coherent — they engage in EU projects that help validate and deploy their diagnostic platform in clinical trial settings, suggesting future collaborations should be framed around clinical validation or companion diagnostics.

How they like to work

Agendia takes both coordinator and partner roles depending on fit — leading when the project scales their own product (MammaPrint) and joining as a specialist when the clinical question extends beyond breast cancer (MoTriColor). The partner network (9 unique partners across 4 countries) reflects a focused clinical-research circle rather than broad scouting.

Collaborated with 9 unique partners across 4 countries, a compact network consistent with clinical oncology consortia rather than broad multi-country platforms.

What sets them apart

Unlike research-stage biotechs, Agendia already markets an approved, reimbursed genomic test used in routine oncology care — they bring a validated commercial diagnostic platform to consortia, not a laboratory prototype. This makes them useful for projects needing real clinical deployment, reimbursement evidence, or integration with hospital workflows rather than basic biomarker discovery.

Highlights from their portfolio

• MammaPrint
  Their largest engagement (EUR 4M EC funding, coordinator role) — an SME-2 grant to roll out their own breast cancer diagnostic test across European clinical practice.
• MoTriColor
  A research-action project applying molecular-guided treatment strategies in advanced colorectal cancer, showing their diagnostic approach extends beyond breast cancer.